目的探讨吸入β2-受体激动剂(舒喘灵)治疗新生儿暂时性呼吸急促(transient Tachypnea of the Newborn TTN)的疗效,并确定新生儿吸入舒喘灵的安全性.方法将2011年10月至2014年6月入住昆明市妇幼保健院的100例TTN患儿随机分为吸入舒喘灵组...目的探讨吸入β2-受体激动剂(舒喘灵)治疗新生儿暂时性呼吸急促(transient Tachypnea of the Newborn TTN)的疗效,并确定新生儿吸入舒喘灵的安全性.方法将2011年10月至2014年6月入住昆明市妇幼保健院的100例TTN患儿随机分为吸入舒喘灵组(治疗组)52人,未吸入组(对照组)48人,胎龄37周至40+3周.治疗组通过舒喘灵喷雾瓶、储雾罩在入院60 min、6 h分别给予0.4 mg舒喘灵气雾剂吸入;对照组按常规治疗.结果 (1)2组患儿在入院后7、12、24 h呼吸急促、呻吟、吸凹征严重程度比较,治疗组较对照组明显减轻和持续时间明显缩短,差异有统计学意义(P<0.05);(2)治疗组用药前后心率无明显增加,2组心率统计学处理,差异无统计学意义(P>0.05);(3)舒喘灵组需要常压给氧、n CPAP治疗时间较对照组缩短,差异有统计学意义(P<0.05);(4)机械通气治疗:舒喘灵组1例(1.9%)、对照组6例(12.5%),差异有统计学意义(P<0.05);(5)2组入院后12 h监测平均p H值、氧分压、二氧化碳分压转归情况比较,差异有统计学意义(P<0.05);(6)在研究过程中,心电监护无1例心律失常发生;52例治疗组患儿均未出现肌肉震颤症状.结论吸入舒喘灵对新生儿暂时性呼吸急促治疗有明显疗效.且临床和实验室检查均未发现不良反应.展开更多
新生儿湿肺症,即新生儿暂时性呼吸急促(Transient Tachypnea of the Newborn,rrrN)是足月儿或近足月儿吸窘迫最常见的原因之一,主要与出生时肺部液体量以及离子转运减少,导致出生时肺部液体较多所致。近年来重症湿肺明显增多,且...新生儿湿肺症,即新生儿暂时性呼吸急促(Transient Tachypnea of the Newborn,rrrN)是足月儿或近足月儿吸窘迫最常见的原因之一,主要与出生时肺部液体量以及离子转运减少,导致出生时肺部液体较多所致。近年来重症湿肺明显增多,且部分病例呼吸困难较严重、持续时间较长,展开更多
Objective To evaluate the efficacy of erythropoietin in prevention and treatment of anemia of prematurity. Methods 119 preterm infants were randomly assigned to receive (treated group,60 neonates) or not to receive(co...Objective To evaluate the efficacy of erythropoietin in prevention and treatment of anemia of prematurity. Methods 119 preterm infants were randomly assigned to receive (treated group,60 neonates) or not to receive(control group, 59 neonates) rhEPO. RhEPO (750IU·kg -1·w -1)was given three times weekly for 4 weeks.Both these two groups received iron and folic acid.Results Treated group had a marked increase of reticulocyte compared with the control group (P<0.01).There were statistically significant differences between these two groups in the rate of weight gain(P<0.05).Condusion Early administration of high dosage of rhEPO can lighten the degree of anemia in展开更多
文摘Objective To evaluate the efficacy of erythropoietin in prevention and treatment of anemia of prematurity. Methods 119 preterm infants were randomly assigned to receive (treated group,60 neonates) or not to receive(control group, 59 neonates) rhEPO. RhEPO (750IU·kg -1·w -1)was given three times weekly for 4 weeks.Both these two groups received iron and folic acid.Results Treated group had a marked increase of reticulocyte compared with the control group (P<0.01).There were statistically significant differences between these two groups in the rate of weight gain(P<0.05).Condusion Early administration of high dosage of rhEPO can lighten the degree of anemia in